Tyler Shaw, Author at Medisphere Research

Merck’s LIPFENDRA® Receives FDA Approval for LDL Cholesterol Reduction

by Tyler Shaw | Jul 21, 2026 | Success Stories

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a...

Merck’s LIPFENDRA® Receives FDA Approval for LDL Cholesterol Reduction

Recent Posts

Recent Comments

Our Locations

Contact

Hours